Companies
Fertin Pharma
an oral-delivery-systems specialist that develops, manufactures and launches chewable nutraceutical and wellness products in partnership with consumer brands, positioning gum as a delivery platform rather than a confectionery product in its own right.
- Country
- Denmark
Commercial
Contract-manufactured nutraceutical & medicated gum; oral-delivery platform (Denmark)
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| food-alt-protein | ✓ | ✓ | ✓ |
Regulatorsfdaefsa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Acquired by Philip Morris International for DKK 5.1 billion (approx. USD 820 million) in September 2021 | biobase.whitefordresearch.com |
| Capacity | Over 3.1 billion units annually | fertin-prod.nmic.nu · fertin.com |
| Certification | cGMP and FDA-approved facilities | biobase.whitefordresearch.com · regnskaber.virk.dk |
| Regulatory approval | Approved by Danish authorities and the US FDA | biobase.whitefordresearch.com · regnskaber.virk.dk |
| Production site | Denmark, Canada, and India | biobase.whitefordresearch.com · wonnda.com · fertin.com · pmi.com |
| Headcount | More than 1,200 employees | fertin-prod.nmic.nu · fertin.com |
| Revenue | DKK 1,104 million (2024) | regnskaber.virk.dk |
Independent sources: biobase.whitefordresearch.com · fertin-prod.nmic.nu · pmi.com · regnskaber.virk.dk · wonnda.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Functional chewing gum | food-alt-protein | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.